Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Q4 2025 Earnings Presentation

31 slides from Lytix Biopharma ASA's earnings presentation, Feb 12, 2026

  1. Slide 1: Oncolytic Molecules that Kill Cancer & Prevent Recurrence

    Oncolytic Molecules that Kill Cancer & Prevent Recurrence Neoadjuvant Immunotherapy with Durable Responses Approaching Commercialization Q4 Earnings Presentation February 12th, 2026

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person

  3. Slide 3: Presenting team

    Presenting team Øystein Rekdal, CEO Gjest Breistein, CFO Founder and scientist-CEO with over two Finance leader with strong track decades in immuno-oncology, leading the record in listed companies, ensuring discovery and development of Lytix’s disciplined financial management innovative peptide-base

  4. Slide 4: Company introduction

    Company introduction Company Overview 4 Non-confidential

  5. Slide 5: Lytix's Therapies Work Through a Two-Phase Mechanism

    Lytix’s Therapies Work Through a Two-Phase Mechanism; Killing Tumors Locally & Activating Broad Systemic Immune Response 5

  6. Slide 6: Ruxotemitide is Potent, Safe and Well-tolerated in Advanced Melanoma

    Ruxotemitide (LTX-315) is Potent, Safe and Well-tolerated in Advanced, Heavily Pre-treated Melanoma Patients in Combination with Pembrolizumab Complete regression in Complete regression in Key Findings injected tumors non-injected tumors Before Treatment Baseline scan 28 mm lesion in left gluteus mu

  7. Slide 7: Current Treatment Options for Resectable Tumors Carry High Risk of Recurrence

    Current Treatment Options for Resectable Tumors Carry High Risk of Recurrence or Low Response Rate Treatment Options for Resectable Tumors Lytix’s First-in-Class Solution Surgery: Cancer can be removed but carries a high risk Kill cancer cells to induce a strong local immune of recurrence. response

  8. Slide 8: Lytix Valuation has Potential to Increase as Assets Enter Clinic

    Lytix Valuation has Potential to Increase as Assets Enter Clinic and Indications are Expanded Pharma Partnerships and/or Investment Drive Company Valuation ILLUSTRATIVE VALUATION COMPANY 2 Drugs, 5 Indications 2 Drugs, 3 Indications 1 Drug, 1 Indication TODAY FUTURE 8 Non-confidential

  9. Slide 9: Q4 Highlights

    Q4 Highlights

  10. Slide 10: Highlights for the Fourth Quarter & Post Quarter End

    Highlights for the Fourth Quarter & Post Quarter End NeoLIPA – Neoadjuvant Melanoma Study Patients Continue to be Relapse Free • Interim results from NeoLIPA presented at the Nordic Melanoma Meeting demonstrating ruxotemitide treatment delivers 44% complete pathological response (100% tumor eliminat

  11. Slide 11: Highlights for the Fourth Quarter & Post Quarter End

    Highlights for the Fourth Quarter & Post Quarter End Business and Financial • Raised NOK 77.3 million in January through a private placement and subsequent offering, strengthening execution capacity. • Independent third-party commercial assessment complete; ruxotemitide and LTX-401 represent multi-

  12. Slide 12: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 12 Non-confidential

  13. Slide 13: Progress Towards Commercialization of Ruxotemitide and Clinical Entry for LTX-401

    Progress Towards Commercialization of Ruxotemitide and Clinical Entry for LTX-401 Population Pre-clinical Phase I Phase II Phase III Partner Ruxotemitide (LTX-315) Pivotal Study Combination with TBD Actively Seeking Partnerships pembrolizumab Monotherapy Basal cell carcinoma Neoadjuvant NeoLIPA rese

  14. Slide 14: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 14 Non-confidential

  15. Slide 15: Exploratory Immune Analysis Demonstrates Reprogramming of Tumors

    Exploratory Immune Analysis Demonstrates Reprogramming of Tumors to Overcome Immunosuppression Findings support ruxotemitide’s potential as a non-surgical, first-line BCC therapy • Immune results presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting - November 2025 • Significant inc

  16. Slide 16: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 16 Non-confidential

  17. Slide 17: NeoLIPA Study Shows Promising Results in Treatment-Naïve Melanoma

    NeoLIPA Study Shows Promising Results in Treatment-Naïve Melanoma (Phase II) Study Overview • Investigator-initiated study led by Dr. Henrik Jespersen at Oslo University Hospital • Ruxotemitide (intratumoral) + pembrolizumab administered prior to surgery • 15 of 27 patients enrolled as of February 2

  18. Slide 18: NeoLIPA Interim Results Demonstrate Strong Anti-Tumor Activity

    NeoLIPA Interim Results Demonstrate Strong Anti-Tumor Activity Clinical Validation of Ruxotemitide Established in Ph II Neoadjuvant Melanoma Interim data presented at Nordic Melanoma Meeting – November 2025, by Dr. Henrik Jespersen and team PATHOLOGICAL MAJOR OVERALL COMPLETE RESPONSE 44% • PATHOLOG

  19. Slide 19: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 19 Non-confidential

  20. Slide 20: LTX-401 is On-track to Enter the Clinic in 2027

    LTX-401 is On-track to Enter the Clinic in 2027 Future development strategy under review to determine optimal timing & pathway for clinical entry • Proprietary asset of Lytix • Partly validated by ruxotemitide’s clinical results due to same mode-of-action • Positive regulatory feedback supports clin

  21. Slide 21: Financials & Outlook

    Financials & Outlook 21 Non-confidential

  22. Slide 22: Key Figures – Profit & Loss

    Key Figures – Profit & Loss Amounts in NOK ‘000 Q4 2025 Q4 2024 H2 2025 H2 2024 FY 2025 FY 2024 Total operating income - 377 - 607 - 11,134 Total operating expenses (21,162) (32,998) (45,420) (56,278) (64,028) (107,029) Loss from operations (21,162) (32,662) (45,420) (55,671) (64,028) (95,896) Loss

  23. Slide 23: Lean Cost Base and Solid Runway into 2026

    Lean Cost Base and Solid Runway into 2026 Total operating expenses Cash and short-term financial investments 32,998 130,791 23,280 24,258 21,540 21,162 117,903 20,009* 100,263 13,451 90,005 22,894 5,157 72,358 16,315 10,984* 13,170 60,181 6,277 4,825 5,905 43,539 (3,209) Q1 24 Q2 24 Q3 24 Q4 24 Q1 2

  24. Slide 24: Key Figures – Balance Sheet

    Key Figures – Balance Sheet Amounts in NOK ‘000 30.06.2025 30.09.2025 31.12.2025 31.12.2024 Assets Property, plant and equipment 18 8 5 42 Right-of-use assets 2565 2,324 2,082 2,589 Trade and other receivables 7,281 3,123 7,078 13,113 Short-term financial investments 60,072 60,923 61,756 - Cash and

  25. Slide 25: Lytix Biopharma's Roadmap to Create Shareholder Value

    Lytix Biopharma’s Roadmap to Create Shareholder Value Non-metastatic skin cancer Neoadjuvant melanoma Deep seated cancer Ruxotemitide: Clear path Ruxotemitide: Phase II LTX-401: Strong preclinical towards commercialization; results in NeoLIPA; results; Significant interest Actively seeking partnersh

  26. Slide 26: Executing on our Strategy

    Executing on our Strategy Lytix Clinical Development • NeoLIPA topline results 2026 • Preparing for a pivotal study for ruxotemitide Verrica - BCC • Preparing for pivotal Phase III trial Pipeline & Partnerships • Evaluating all strategic opportunities to accelerate the development of LTX-401 • Strat

  27. Slide 27: Q&A

    Q&A 27 Non-confidential

  28. Slide 28: Interim Financial Statements

    Interim Financial Statements 28 Non-confidential

  29. Slide 29: Condensed Interim Statement of Profit & Loss

    Condensed Interim Statement of Profit & Loss Unaudited Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q4 2025 Q4 2024 H2 2025 H2 2024 FY 2025 FY 2024 Revenue - 377 - 607 - 11,134 Other operating income - - - - - - Total operating income - 377 - 607 - 11,134 Payroll and related expe

  30. Slide 30: Condensed Interim Statement of Financial Position

    Condensed Interim Statement of Financial Position Unaudited Unaudited Unaudited Amounts in NOK thousands 30.06.2025 30.09.2025 31.12.2025 31.12.2024 Assets Non-current assets Property, plant and equipment 18 8 5 42 Right-of-use assets 2,565 2,324 2,082 2,589 Total non-current assets 2,583 2,332 2,08

  31. Slide 31: Condensed Interim Statement of Cash Flows

    Condensed Interim Statement of Cash Flows Unaudited Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q4 2025 Q4 2024 H2 2025 H2 2024 FY 2025 FY 2024 Cash flows from operating activities Loss for the period (18,660) (31,910) (41,998) (54,648) (59,982) (94,265) Adjustments for: Depreci

Lytix Biopharma — Q4 2025 Earnings Presentation on 6ix